Ignite Creation Date:
2024-05-06 @ 9:45 AM
Last Modification Date:
2024-10-26 @ 12:19 PM
Study NCT ID:
NCT03061370
Status:
COMPLETED
Last Update Posted:
2020-03-26
First Post:
2017-02-17
Brief Title:
Sarcopenia and Visceral Obesity in Esophageal and Gastric Cancer
Sponsor:
St Jamess Hospital Ireland
Organization:
St Jamess Hospital Ireland
Study Overview
Official Title:
An Investigation of the Prevalence and Clinical Impact of Sarcopenia and Visceral Obesity Among Patients With Upper Gastrointestinal Malignancies
Status:
COMPLETED
Status Verified Date:
2020-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In line with improvements in oncologic outcome for patients with esophageal cancer the attritional impact of curative treatment with respect to functional status and health-related quality of life HR-QL in survivorship is increasingly an important focus Functional recovery after surgery for esophageal cancer is commonly confounded by anorexia and early satiety which may reduce oral nutrient intake with consequent malnutrition and weight loss One in three disease-free patients has more than fifteen percent body weight loss at three years after esophagectomy
The ESPEN Special Interest Group on cachexia-anorexia in chronic wasting diseases has defined sarcopenia as skeletal muscle index SMI of 39 cm2m2 for women and 55cm2m2 for men while similar cut-off points have been validated in upper gastrointestinal and respiratory malignancies less than 385 cm2m2 for women and 524 cm2m2 for men The European Working Group on Sarcopenia in Older People EWGSOP additionally recommends that assessment should also include determination of muscle function for example gait speed or grip strength where possible
The presence of sarcopenia is associated with increase treatment-associated morbidity impaired HR-QL reduced physical and role functioning and increased pain scores in older adults In addition a previous longitudinal study demonstrated that the decline in HR-QL over a six year period in older adults was accelerated in the presence of sarcopenia As such sarcopenia may represent a modifiable barrier to recovery and subsequent retention of HR-QL and functional status and may reinforce a persistent illness identity among patients following potentially curative treatment for esophageal cancer
The ESPEN Special Interest Group on cachexia-anorexia in chronic wasting diseases has defined sarcopenia as skeletal muscle index SMI of 39 cm2m2 for women and 55cm2m2 for men while similar cut-off points have been validated in upper gastrointestinal and respiratory malignancies less than 385 cm2m2 for women and 524 cm2m2 for men The European Working Group on Sarcopenia in Older People EWGSOP additionally recommends that assessment should also include determination of muscle function for example gait speed or grip strength where possible
The presence of sarcopenia is associated with increase treatment-associated morbidity impaired HR-QL reduced physical and role functioning and increased pain scores in older adults In addition a previous longitudinal study demonstrated that the decline in HR-QL over a six year period in older adults was accelerated in the presence of sarcopenia As such sarcopenia may represent a modifiable barrier to recovery and subsequent retention of HR-QL and functional status and may reinforce a persistent illness identity among patients following potentially curative treatment for esophageal cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None